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As a result of using more intensive treatment
protocols, the prognosis of acute lymphoblastic
leukemia (ALL) in childhood has dramatically im-
proved over the past 30 years, reaching cure rates
of at least 70% [1]. This success rate is attributed
to the usage of more intensive systemic (i.e.
chemotherapeutic) therapy and to the prophylac-
tic treatment of the central nervous system (CNS)
consisting of chemotherapy and/or radiotherapy
[2]. With the rising number of long-term sur-
vivors, it has become evident that more intensive
therapies, especially more efficacious CNS pro-
phylaxis, can induce late toxicities, particularly
neuropsychological (cognitive) disabilities [3–7]. If
the deleterious role of cranial radiotherapy, espe-
cially if given at a younger age and at higher
cumulative doses, is well established [8, 9], the
potential role of intrathecal and/or intravenous
With the use of more intensive regimens in-
cluding prophylactic CNS treatment, the progno-
sis of children with ALL has dramatically im-
proved over the last three decades. The aim of this
cross-sectional, nationwide study was to compre-
hensively assess long-term toxicity in ALL sur-
vivors, with special attention given to neuropsy-
chological morbidity, and to look for possible dif-
ferences in cognitive outcome between children
having received prophylactic cranial irradiation
and those not having received it. 
Between 1994 and 1996, long-term survivors
of ALL were assessed in a multi-center setting ac-
cording to a standardized protocol which included,
besides usual clinical and laboratory investigations,
a comprehensive endocrine work-up. Additionally,
children having received anthracyclines were
checked for possible late cardio-toxicity with
echocardiography and ECG. Intellectual perform-
ance was evaluated with standardized neuro-
psychological tests (age-adapted versions of the
Wechsler test). 
One-hundred and fifty patients were eligible
for the study. The median age at diagnosis was 5
years and at evaluation 16 years, for a median fol-
low-up of 10 years. Thirty-five patients had cra-
nial irradiation as part of the prophylactic CNS
treatment. One-hundred and forty (93%) of the
150 eligible patients were completely evaluated in
terms of global long-term toxicity: 117 (83%)
long-term survivors had no (n = 61) or only mini-
mal (n = 56) late toxicity; 19 (14%) suffered from
moderate impairments; 4 (3%) showed severe so-
matic or neuropsychological sequelae. Intellectual
performance could be assessed in 147 (98%) of the
150 eligible patients. The mean global, verbal and
non-verbal IQs (103, 105 and 101 respectively) of
the ALL survivors as a group were comparable
with those found in the general population. The
results of the comparison between children having
and those not having received prophylactic cranial
irradiation showed: 1) significantly higher scores
in chemotherapy-only treated patients, both for
the global and the verbal performances; 2) signifi-
cantly poorer results in specific items of the Wechs-
ler test (short-term verbal memory, arithmetics,
concentration/speed of processing) in irradiated
children. 
These findings which show the deleterious
role of cranial irradiation correlate well with many
other reports found in the literature. However,
they could have been influenced by the signifi-
cantly longer time interval observed between ther-
apy and evaluation in our irradiated patients.
Prospective studies are needed to further charac-
terize the potential neuropsychological hazards of
chemotherapy and their evolution over time. 
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chemotherapy (especially methotrexate [MTX]) is
less clear. The few prospective studies available
seem to indicate that the development of cognitive
disabilities increases over time, both after receiv-
ing chemotherapy alone and chemo-radiotherapy
as CNS prophylaxis, but that there is no clear-cut
difference between those children having received
prophylactic CNS irradiation and those not hav-
ing received it [10, 11]. The different results re-
ported in other studies [12–14] may be due to the
methodological difficulties and the many pitfalls
encountered when assessing neuropsychological
disabilities in long-term survivors [15]. Compre-
hensive studies assessing the whole spectrum of late
effects and their global impact on socio-profes-
sional insertion of these survivors are still lacking.
Since 1976 the Swiss Pediatric Oncology
Group (SPOG) has registered almost every case of
childhood ALL in Switzerland and has recorded
data relating therapeutic regimens and their out-
come. In the early 90’s SPOG developed and then
checked a standardized set of investigations in a
pilot-study [16] to comprehensively assess late ef-
fects of childhood cancer on a cross-sectional basis.
The nationwide study began in April 1994 in the
8 SPOG institutions. We will focus hereafter on
the results attained in the subgroup of ALL long-
term survivors, paying special attention to neu-
ropsychological impairments, and also shortly de-
scribing the findings in the field of endocrinology,
the cardio-pulmonary and digestive systems, as
well as secondary malignancies.
Patients and methods
Between April 1994 and May 1996, more than 500
long-term survivors of childhood cancer entered the mul-
ticenter, cross-sectional study, of whom 152 had ALL di-
agnosed between 1.1.1976 and 31.12.1989. To be eligible,
patients had to be alive with no evidence of disease for 5
years or more after diagnosis or relapse, and to be off ther-
apy for at least 2 years. Two patients having undergone
bone marrow transplantation (BMT) were excluded. 
The study protocol had been approved by the local
Ethics Committees and informed consent was obtained
from each of the 150 study participants. The patients came
to the clinic in the morning; medical and psycho-social
histories as well as clinical examination were realized and
summarized according to the standardized study forms,
blood and urine probes were taken. All laboratory inves-
tigations (Appendix I), including endocrine work-up with
the exception of IGF-1 and IGF-BP3 (centralized deter-
mination and interpretation in the Unit for paediatric en-
docrinology at the University Hospital in Geneva) were
done and the results interpreted locally. In the afternoon,
neuropsychological testing using age- and language-
adapted (German, French and Italian) versions of the re-
vised Wechsler Intelligence Test [17] was realized and in-
terpreted by one of the 2 certified paediatric neuro-psy-
chologists specifically enrolled and trained for the Late Ef-
fects Study. The evaluation of psycho-social adjustment
was based on anamnestical data regarding contact with
peers (integration in sport, school, youth groups), part-
nership, current employment status, insurance questions
and, in older patients, marital status and family.
The main characteristics of the patients are summa-
rized in Table 1. One-hundred and thirty-four patients
were in CR1, 12 in CR2 (4 each after isolated testicular,
isolated CNS or BM relapse) and 4 patients in CR3. Note-
worthy, 146 children (97%) were so called “study” pa-
tients, i.e. officially enrolled and treated according to stan-
dardized protocols: 82 on SPOG, 37 on POG and 7 on old
CALGB studies. One-hundred and four children were
treated with chemotherapy only, 5 others were given bi-
lateral testicular irradiation for a local relapse and 41 chil-
dren received prophylactic or therapeutic CNS irradiation
(Table 2). 
All toxicities found were recorded in a “Summary
Sheet” and computerized for further analysis. The global
impact of the late effects on the daily life of the patients
was scored according to the scale described in Table III of
reference 16. Neuropsychological aspects were then stud-
ied in more detail, taking only patients (n = 141) who had
no CNS involvement and looking for possible differences
between children having and those not having received
prophylactic CNS irradiation. The Mann-Whitney U-
test [18] was used for the statistical analysis of IQ data. A
p-value of <0.05 was considered to be statistically signifi-
cant.
ALL phenotypes
NOS 10
pre-B cell 132
T-cell 5
B-cell 3
median range
Age at diagnosis (yrs) 5.0 0.5–14.5
Age at study (yrs) 16.0 6.5–30.5
Follow-up (yrs) 10.0 5.0–21.5
Table 1
Patients characteris-
tics (n = 150 patients;
F = 70, M = 80).
Chemotherapy only, no radiotherapy at all 104 children
Chemotherapy and testicular radiotherapy only 5 children
Chemotherapy and cranial or cranio-spinal radiotherapy 41 children
Cranio-spinal radiotherapy doses:
conventional fractionation, dose/fraction: 150–200 cGy
total doses: 
patients with cranial radiotherapy only (n = 34): 18–30 Gy (mean 23 Gy)
patients with cranio-spinal radiotherapy (n = 7): cranial 18–48 Gy (mean 26.5 Gy)
spinal 18–30 Gy (mean 22.3 Gy)
Table 2
Treatment details 
(n = 150 patients).
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General data
For 140 (93%) of the 150 ALL long-term sur-
vivors complete results were available. The distri-
bution of the overall severity of late effects is sum-
marized in Table 3: 117 (83%) had no (grade 0) or
only minimal (grade 1) troubles, not affecting pa-
tients’ daily lives; 19 (14%) had moderate (grade 2)
late toxicity, needing medical attention and/or
therapy but not restraining quotidian or profes-
sional activities; only 4 (3%) patients were severely
(grade 3 or 4) affected. Thus, one of the 4 severely
affected patients needed specialized schooling and
remained fully institution-dependent as a young
adult. This patient had severe measles-encephali-
tis while on maintenance chemotherapy. 
One-hundred and thirty-two (94%) of the 140
survivors went to a normal class, while 6 (4%)
needed enrollment in a small-class or extra-tuto-
rial support and 2 (2%) were schooled in a spe-
cialized institution. Psycho-social adjustment, as
assessed through a short standardized anamnesis
looking for age-adapted social insertion (peer-
groups, sport, partner, employment, insurance and
marital status), was considered adequate in 126 pa-
tients (90%), problematic in 12 (8.5%) and poor in
2 (1.5%). 
Non-neuropsychological data
The somatic late toxicity effects are summa-
rized in Table 4:
Endocrine problems were found in 20 children
(14%); 11 had gonadal dysfunctions: 5 males
showed clinical (soft and abnormally small testes)
and biological (normal free testosterone by raised
FSH levels) signs of isolated exocrine dysfunction
and were therefore at high risk of infertility; 2
other boys had clinical (small testes and delayed
puberty, retarded bone age) and biological (low
testosterone, high FSH and LH levels) signs of
global gonadal failure and received testosterone
substitution. Five boys had been given bilateral
testicular irradiation (18–24 Gy), the others re-
ceived intensive chemotherapy including cy-
clophosphamide, one for T-cell and one for ma-
ture B-cell ALL. Four girls had persistent (more
than 6 months) oligomenorrhoea or amenorrhoea:
in 2 cases, a clearcut hypogonadotropic hypogo-
nadism after cranial irradiation (cumulative dose
30–40 Gy) could be demonstrated; one girl devel-
oped amenorrhoea after a voluntary drastic diet
and weight loss; in the last case, no clear origin
could be found. It is noteworthy that 3 survivors
(2F, 1M) had a total of 4 absolutely healthy babies.
Seven patients developed growth failure: 4
children had received cranial radiotherapy (24 Gy
prophylactic in 3, 30 Gy therapeutic in 1) and 
presented with evidence of GH-deficiency in both
screening tests (low IGF-1 and IGF-BP3) and after
insuline-arginine induced hypoglycemia. Two
other patients having undergone therapeutic
cranio-spinal irradiation remained below –2SD
from their expected final height, with distinct dis-
proportionated short stature (sitting height/leg
length <1.0). One girl developed an unrecognized,
therefore untreated combination of precocious
puberty and GH-deficiency after cranial (30 Gy)
irradiation. 
The last patient with endocrine troubles pre-
sented with primary hypothyroidism after cranio-
spinal irradiation and was appropriately treated
with substitution therapy.
Late cardio-vascular toxicity was a rather rare
event: 2 asymptomatic patients had echocardio-
graphic signs of left-ventricular cardio-myopathy
(WHO grade 1) with slightly reduced shortening-
fraction (25–29%) as an isolated finding. Interest-
ingly, both had received moderate cumulative an-
thracycline doses (270 and 225 mg/m2 daunoru-
bicine) but belonged to the “oldest” patients in
terms of follow-up (15 and 16.5 years after the end
of treatment). Arterial hypertension, as defined in
(19), was found in 2 long-term survivors: in one, it
Results
Severity score / type number of patients percentage
Overall severity of late effects
0 61 43.5%
1 56 40%
2 19 13.5%
3 3 2%
4 1 1%
Schooling
Normal class 132 94%
Small class/Extra-tutorial 6 4.5%
Specialized institution 2 1.5%
Psycho-social adjustment (relationships with peers (school, sport, hobbies), partner, job history)
Normal 126 90%
Problematic 12 8.5%
Poor 2 1.5%
Table 3
Global results 
(n = 140 patients 
assessed).
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could be considered idiopathic; in the other, it was
clearly secondary to the initial uric acid nephropa-
thy characteristic of T-cell ALL with slight but
persistent elevation of serum creatinine.
Pulmonary sequelae were very rarely encoun-
tered: 2 asymptomatic patients had a moderate
restrictive syndrome (WHO grade 2, VC 65–79%
of the normal value), both clearly related to severe
interstitial pneumopathy (1 VZV and 1 PCP-in-
fection) during chemotherapy. 
Two children had signs of chronic liver (MTX-
induced?) toxicity (constantly raised SGPT levels),
one other suffered from chronic HCV infection
and was started on alfa-Interferon therapy. 
Of interest, one patient developed a secondary
malignancy 8.5 years after the diagnosis of common
ALL (chemotherapy and prophylactic [24 Gy] cra-
nial irradiation). This girl developed an embryonal
rhabdomyosarcoma of the left zygomatic area. She
could be salvaged using an aggressive chemo-
radiotherapeutic approach. No secondary CNS
malignancies were observed. 
Endocrine system: n = 20 patients (14%)
Gonadal dysfunctions: n = 11
– 7 males with primary gonadal failure:
5 after bilateral testicular radiotherapy (18–24 Gy) for testicular relapse
2 (1 each with T-cell and mature B-cell ALL) after cyclophosphamide
– 4 females with oligo- or amenorrhea: 
2 with hypogonadotropic hypogonadism after cranial radiotherapy 
1 with secondary amenorrhea of exogen origin (drastic weight loss)
1 with oligomenorrhea of unknown origin
Primary hypothyreosis: n = 1
– after cranio-spinal radiotherapy; eltroxine substitution.
Growth failure: n = 7
– 4 with GH-deficiency after cranial radiotherapy (24 Gy in 3 and 30 Gy in 1 patient[s])
– 2 patients with GH-deficiency and poor axial vertebral growth after cranio-spinal radiotherapy 
– 1 girl with unrecognized pubertas praecox and GH-deficiency after cranial (30 Gy) radiotherapy 
Cardio-vascular system: n = 4 patients (3%)
– 2 with cardiomyopathy, WHO grade 1 (SF 25–29%)
– 2 with arterial hypertension (1 of unclear origin, 1 persistent after initial uric acid nephropathy in a T-cell ALL)
Lungs: n = 2 patients (1.5%)
– with restrictive syndrome, WHO grade 2 (VC 65–79% of normal) after severe interstitial pneumopathy (1 VZV, 1 PCP)
Liver and digestive system: n = 3 patients (2%)
– 2 with isolated raised SGPT levels
– 1 with a chronic HCV infection
Table 4
Somatic late effects
(n = 140 patients 
assessed).
mean ± SD range
global IQ 103 ± 14 68–144
verbal IQ 105 ± 14 68–135
performance IQ 101 ± 14 54–144
Patients with IQ under 85 (<–1 SD)
global IQ 12/147 8%
performance IQ 13/147 9%
verbal IQ 17/147 11.5%
overall 27/147 18.5%
Table 5
Global intellectual
achievement (n = 147
patients assessed).
Neuropsychological data
ALL survivors as a group
Data from 147 out of the 150 patients (98%)
were available; 3 patients have been excluded be-
cause of absence of data, trisomy 21 and severe
PM-retardation (the child with severe measles en-
cephalitis). As shown in Table 5 no differences
could be found in terms of global, verbal or non-
verbal (“performance”) IQ’s between ALL sur-
vivors as a group and the general population (mean
IQ 100, SD ± 15). Also, the proportion of children
with learning disabilities (i.e. an IQ under 85) was
comparable in both groups (ALL survivors 18.5%,
general population 16%, as expected from the
normal distribution curve).
Intellectual performances according to the prophylactic
CNS treatment
Patients with pre-existing conditions poten-
tially affecting the CNS, as well as patients with
leukemic CNS-involvement at diagnosis or later,
were excluded from the evaluation. One-hundred
and forty-one children and young adults remained
eligible: 35 received prophylactic CNS radiother-
apy and 106 did not. With the exception of the age
at study, which was for historical reasons, higher in
irradiated children, no differences were found in
the major patients’ characteristics, including 
socio-economic status of the family (SES, see Ap-
pendix I) (Table 6, top). All three IQ scores were
higher in the non-irradiated children, a statistically
significant difference being found both for global
and verbal IQ’s (Table 6, middle). When looking at
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the subgroup of long-term survivors with IQ’s
under 85 (Table 6, bottom), no difference in per-
centage was found between the 2 groups for the
global intellectual performances (global IQ 10%
vs. 8.5%). However, when looking separately at
only verbal or only non-verbal performances, irra-
diated children were obviously more often diag-
nosed as “learning-disabled” (19.5% vs. 9.5% for
the verbal, 17% vs. 6.5% for the non-verbal per-
formances) compared to their non-irradiated
counterparts. The results obtained in each indi-
vidual item of the Wechsler test were then com-
pared and summarized in Table 7: significantly
poorer results in irradiated children were found in
arithmetic (AR), short-term verbal memory (digit
span, DS) and speed of processing, visuomotor co-
ordination (codes, CO) but not in the 8 other
items, as illustrated for block design (BD).
To study the independent impact of cranial ra-
diotherapy, in front of other potential variables in-
fluencing cognitive outcome such as sex and length
of the follow-up, a multivariate analysis was real-
ized (Table 8). It confirmed that, corrected for gen-
der and follow-up, prophylactic cranial irradiation
remained an independent prognostic outcome fac-
tor, influencing both global and verbal IQs.
group A p group B 
(no cranial irradiation) (with cranial irradiation)
n 106 35
Age at diagnosis (mean ± SD) 5.6 ± 3.4 n.s. 5.9 ± 3.2
Age at study (mean ± SD) 14.5 ± 4.3 <0.001 21.3 ± 3.4
SES (mean ± SD) 6.9 ± 2.34 n.s. 7.33 ± 2.03
M: F 55: 51 (1.08) n.s. 20: 15 (1.33)
g IQ (mean ± SD) 105.6 ± 14.4 0.016 99.5 ± 10.7
p IQ (mean ± SD) 106.7 ± 14.4 n.s. (0.09) 102.1 ± 13.8
v IQ (mean ± SD) 103.4 ± 14.0 0.009 96.8 ± 12.4
Patients with IQ under 85 (<–1 SD)
global IQ 9/106 (8.5%) 4/41 (10%)
performance IQ 7/106 (6.5%) 7/41 (17%)
verbal IQ 10/106 (9.5%) 8/41 (19.5%)
Table 6
Intellectual achieve-
ment according to
CNS prophylaxis.
group A p group B
DS (mean ± SD) 9.87 ± 2.41 0.007 8.43 ± 2.31
AR (mean ± SD) 10.51 ± 2.88 0.01 9.28 ± 2.50
CO (mean ± SD) 10.53 ± 2.60 0.006 9.03 ± 2.45
BD (mean ± SD) 11.06 ± 3.05 0.51 10.60 ± 2.73
DS = digit dpan; AR = arithmetic’s; CO = codes; BD = block design
Table 7
Subtle neuropsycho-
logical deficits.
Multiple regression analysis
Dependent variable: pIQ
Parameter Estimate Standard T p value
Error Statistic
Constant 109.729 5.53661 19.8188 0.0000
Follow-up 0.296213 0.402483 0.735963 0.4630
Sex –4.54413 2.32716 –1.95265 0.0529
XRT –8.2953 3.70572 –2.23851 0.0268
Discussion
Improvement in the survival of children with
ALL has been dramatic over the past 30 years.
Therefore, the question of long-term performance
and eventual sequelae in the biologically cured pa-
tients is becoming always more relevant. Due to
the small size of the country and to the relatively
sedentary population, SPOG was able to register
and follow, since 1976, the vast majority (up to al-
most 90%) of children with ALL in Switzerland
[20]. For the same reasons, the group of ALL-sur-
vivors assessed in the SPOG Late Effects Study
and presented here can be considered to be highly
representative, making this study one of the few
population-based studies available.
The global results in terms of long-term
health-status were encouraging: 84% of all ALL
long-term survivors presented no or only minimal
late toxicity. Ninety-four percent enjoyed normal
schooling and 90% an adequate psycho-social in-
sertion. Life-threatening late effects remained a
Table 8
Impact of cranial 
radiotherapy, gender
and length of follow-
up: multivariate
analysis.
rare event: anthracycline-induced cardio-myopathy
was found only in 2 of the 140 patients (1.5%) eval-
uated, after rather moderate cumulative doses (225
and 270 mg/m2) of daunorubicine. Interestingly, the
two affected patients had the longest follow-up (15
and 16.5 years after diagnosis) among the anthracy-
cline-treated subgroup, emphasizing the impor-
tance of long-term (life-long?) cardiac monitoring
[21, 22]. Late pulmonary toxicity was found in only
2 other patients; in both, a clear-cut relationship was
linked to previous severe interstitial pneumopathy
while on therapy. In contrast to others [23], we could
not observe specific toxicity although the vast ma-
jority of our patients (75%) received prolonged low-
dose MTX maintenance therapy. It must be borne
in mind, however, that based on the recommenda-
tions of some authors [24] and the results of our
pilot-study [16], pulmonary function tests were not
routinely performed.
Having also included patients with relapses
(hematological, testicular, CNS), one could expect
a relatively high percentage of patients presenting
with late endocrine troubles, especially growth
failure and gonadal dysfunction. In the vast ma-
jority of the cases, the late effects could be related
to specific components of the anti-leukemic treat-
ment, as described in the literature: growth hor-
mone (GH) deficiency in patients having received
24 or more Gy cranial irradiation [25]; poor verte-
bral longitudinal growth resulting in dispropor-
tionated short stature [26] after cranio-spinal irra-
diation (30 or more Gy to the spine), combined
precocious puberty and GH-deficiency in a girl
with intermediate-dose (30 Gy) cranial radio-ther-
apy [27]; exocrine and endocrine gonadal dysfunc-
tions after testicular irradiation or high cumulative
doses of alkylating agents [28, 29].
Neuropsychological (i.e. cognitive) sequelae
are of great concern in long-term survivors of
childhood ALL. Many papers describe the occur-
rence of late CNS toxicity caused by both cranial
irradiation and i.t. or i.v. chemotherapy, especially
MTX (see thereafter). 
In the present study, the global intellectual
performance of ALL-survivors as a group was
comparable to that found in the general popula-
tion and the same was true for the percentage of
patients presenting with learning disabilities (IQ
under 85). The mean IQs observed in ALL sur-
vivors were not significantly different from those
theoretically expected in a random population of
healthy Swiss children and adolescents (mean IQ
of 100, standard deviation of 15, percentage of
learning disabilities (i.e. gIQ <85) (16%). 
These objective “psycho-metric” findings
were confirmed by the more subjective and “psy-
cho-dynamic” data on schooling and socio-profes-
sional achievement.
Only 35 (25%) out of 141 children had been
treated with prophylactic CNS irradiation. When
analyzing this subgroup separately and comparing
the results with the non-irradiated patients, two in-
teresting findings could be observed.
First, irradiated children showed lower IQ
scores with a statistically significant difference for
both global (p = 0.016) and verbal (p = 0.009) IQ’s.
This deleterious effect of cranial irradiation is well
described in the literature [8, 9, 30] and is more
pronounced the younger the age at treatment. It is
noteworthy, however, that all three mean IQ scores
of the irradiated children in the present study were
in the normal range (gIQ 100, vIQ 97, pIQ 102)
indicating no differences, in terms of IQ points, of
clinical relevance: a finding also reported in an-
other cross-sectional study [31]. The second im-
portant finding was the fact that the proportion of
patients with so-called “learning disabilities” (i.e.
IQ under 85) was significantly higher in irradiated
than in non-irradiated children for both verbal and
non-verbal performances: 20% vs. 10%, and 17%
vs. 7% respectively. The suspicion of a higher in-
cidence of subtle and specific neuro-psychological
deficits in the former group could be confirmed by
the study of the individual items of the Wechsler
test. In three out of the 11 items, significantly
poorer results were found in the irradiated group,
with lower scores in arithmetic, short-term verbal
memory, visuomotor coordination and speed of
processing. Similar results were reported in the
study of Ivnik et al. [31] and by other authors
[32–35]. These subtle cognitive deficits could be of
greater practical relevance, directly affecting the
ability to function correctly at school and later in
jobs, when memory, concentration and speed of
processing become more important and discrimi-
native. These findings are relevant also to the de-
sign of interventional strategies at school [36] or
professional counseling.
When considering these results, two major as-
pects should be kept in mind. 
First, the prophylactic CNS radiation doses
applied to the children of this study were rather
high, ranging from 18 to 30 Gy (mean 23 Gy)
which is distinctly higher than in the vast majority
of currently running ALL protocols typically using
12 Gy whole brain irradiation. Hence, our obser-
vations of higher neurotoxicity in irradiated chil-
dren could be of no relevance for patients enrolled
on current treatment protocols which would in-
clude prophylactic CNS irradiation. A recently
published study from the German BFM group re-
ported no striking cognitive deficiencies in former
ALL children treated with 12 Gy prophylactic cra-
nial irradiation [37]. Moreover, another recent
paper from a Finnish group found no statistically
significant differences either in neurocognitive
performances nor in the cerebral glucose metabo-
lism between children with ALL having received
or not CNS irradiation [38]. This points out the
potential role of the leukemia itself in the devel-
oping of late neurocognitive deficits. On the other
hand, reports on neurocognitive deficits following
chemotherapy-only regimens appear in the litera-
ture [39, 40]. 
Second, the interval between treatment and
evaluation was significantly longer in irradiated
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children than in non-irradiated ones. This could
have been a potentially serious bias, since in both
populations studied (but especially in irradiated
children) cognitive late effects might become more
severe with time [10, 11]. Nevertheless, the multi-
variate analysis pointed out the role of cranial ra-
diotherapy as a unique independent prognostic
factor on global and verbal IQs, when corrected for
sex and length of follow-up. Neither gender (al-
though females scored slightly poorer than males
in vIQ) nor duration of follow-up showed the same
statistically significant impact. 
Other insidious long-term effects of cranial ir-
radiation, which have not been reported after
chemotherapy-only regimens, like the occurrence
of secondary malignant neoplasms of the brain [41]
or of the thyroid [42], must be borne in mind when
following irradiated survivors of childhood ALL.
These observations add weight to the strategy of
restricting prophylactic cranial irradiation to chil-
dren who are at high risk of CNS relapse.
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Appendix I: Standardized assessment protocol 
– patient’s history (medical and psycho-social) 
– standardized clinical investigation, including weight, standing
and sitting height, blood pressure, screening audiometry
(Phonac®)
– laboratory (CBC, lytes, liver enzymes, glomerular and tubular
function)
– endocrinological work-up: Tanner’s pubertal status, age at
menarche, bone age, fT4, TSH, FSH/LH, free β-oestradiol 
(females) or free testosterone (males), IGF-1/IGF-BP3
– rest echocardiography and ECG (patients treated with anthra-
cyclines)
– pulmonary function tests (patients with respiratory symptoms)
– neuropsychological evaluation: WISC-R <16 yrs of age, WAIS-
R in older patients
– SES (socio-economic status of the family): score based on
father’s profession and mother’s schooling (scale 1-12, a higher
score denoting poorer SES)
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